Enbee - Tablet Entecavir - 0.5mg 20 Tablet(s) / Box Jenphar Bangladesh Ltd. Introduction: Enbee is used in the treatment of HIV infection and chronic hepatitis B virus (HBV) infection. It prevents the multiplication of virus in human cells. This stops the virus from producing new viruses and clears up your infection. Enbee is not a cure for HIV or AIDS and only helps to decrease the amount of HIV in your body. This helps to lower your risk of getting HIV-related complications and improves your lifespan. It is prescribed in combination with other HIV medicines. Your doctor will recommend the best medicines for you and will decide the doses that you need. Follow... Uses of Enbee: Chronic hepatitis B virus (HBV) infection Side effects of Enbee: HeadacheDizzinessTirednessNausea How to use Enbee: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Enbee is to be taken empty stomach. How Enbee works: Enbee is an antiviral medication. It prevents the multiplication of virus in human cells. This stops the virus from producing new viruses and clears up your infection. What if you forget to take Enbee?: If you miss a dose of Enbee, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose. Indication: Chronic hepatitis B Administration: Should be taken on an empty stomach. Take at least 2 hr after a meal & 2 hr before the next meal. Use oral solution when needed for renal impairment dosage adjustments. Adult Dose: Chronic Hepatitis B Indicated for treatment of CHB with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease Nucleoside inhibitor treatment-naïve with compensated liver disease (adults and adolescents ?16 yr): 0.5 mg PO qDay Lamivudine-refractory or known lamivudine or telbivudine resistance substitutions (adults and adolescents ?16 yr): 1 mg PO qDay Decompensated liver disease (adults): 1 mg PO qDay Child Dose: Chronic Hepatitis B Indicated for treatment of CHB with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease in children ?2 years and weigh at least 10 kg 16 years: As adult Renal Dose: Renal Impairment Usual daily dose (0.5 mg) CrCl ?50 mL/min: No dosage adjustment required CrCl 30-49 mL/min: Reduce to 0.25 mg/day or 0.5 mg q48hr CrCl 10-29 mL/min: Reduce to 0.15 mg/day or 0.5 mg q72hr CrCl <10 mL/min, hemodialysis, or CAPD: 0.05 mg/day or 0.5 mg q7days Lamivudine-refractory/decompensated liver disease daily dose (1 mg) CrCl ?50 mL/min: No dosage adjustment required CrCl 30-49 mL/min: Reduce to 0.5 mg/day or 1 mg q48hr CrCl 10-29 mL/min: Reduce to 0.3 mg/day or 1 mg q72hr CrCl <10 mL/min, hemodialysis, or CAPD: 0.1 mg/day or 1 mg q7days Contraindication: Entecavir is contraindicated in patients with previously demonstrated hypersensitivity to Entecavir or any component of the product. Mode of Action: Selective HBV DNA polymerase inhibitor; inhibition blocks reverse transcriptase activity, which in turn reduces viral DNA synthesis Precaution: Lactic acidosis: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported with the use of nucleoside analogues alone or in combination with antiretrovirals.Exacerbations of hepatitis after discontinuation of treatment: Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including Entecavir. Lactation: excretion in milk unknown/not recommended Side Effect: 1-10% Fatigue (1-3%),Headache (2-4%),Dizziness,Nausea <1% Diarrhea,Dyspepsia,Vomiting,Somnolence,Insomnia Pregnancy Category Note: Pregnancy Prospective pregnancy data from the APR are not sufficient to adequately assess the risk of birth defects, miscarriage or adverse maternal or fetal outcomes; use during pregnancy has been evaluated in a limited number of individuals reported to APR and number of exposures to entecavir is insufficient to make a risk assessment compared to a reference population; rate of miscarriage is not reported in APR; all pregnancies have a background risk of birth defect, loss, or other adverse outcomes Lactation Not known whether drug is present in human breast milk, affects human milk production, or has effects on the... Interaction: Drugs that reduce renal function or compete for active tubular secretion may increase serum conc of either entecavir or co-administered drug.